前列腺癌术后剂量强化放疗:PKUFH 随机 3 期试验长期结果
PKUFH 单中心随机 3 期试验纳入 144 例前列腺癌根治术后高危患者,1:1 随机接受 72 Gy/36 次或 66 Gy/33 次图像引导调强放疗。中位随访 89.5 个月,7 年生化无进展生存(bPFS)两组无显著差异(70.3% vs 61.2%,HR 0.73,95%CI 0.41-1.29,P=.274);Gleason 评分 8-10 分患者中 72 Gy 组 bPFS 显著改善(66.5% vs 30.2%,HR 0.37,95%CI 0.17-0.82,P=.012)。
要点
- 7 年 bPFS 在 72 Gy 与 66 Gy 组间无显著差异(70.3% vs 61.2%,HR 0.73,P=.274)。
- Gleason 评分 8-10 分患者中 72 Gy 组 7 年 bPFS 显著优于 66 Gy 组(66.5% vs 30.2%,HR 0.37,P=.012)。
- 多切缘阳性患者中 72 Gy 组 7 年 bPFS 显著优于单切缘阳性(82.5% vs 57.5%,HR 0.36,P=.037)。
核心结论
- 7 年 bPFS 结果证实既往发现:72 Gy 剂量强化相比 66 Gy 方案未改善 7 年 bPFS、DMFS、CSS 或 OS。
- Gleason 评分 8-10 分或多切缘阳性患者可能从 72 Gy 方案获益,但需进一步前瞻性研究。
研究设计与样本
- 随机、单中心、PKUFH 3 期试验,纳入 pT3-4 期、切缘阳性或根治性前列腺切除术后前列腺特异性抗原升高≥0.2 ng/mL 的患者。
- 2011 年 9 月至 2016 年 11 月入组 144 例,1:1 随机分配至 72 Gy/36 次组(73 例)或 66 Gy/33 次组(71 例),均接受图像引导调强放疗。
- 主要终点为 bPFS,次要终点为 DMFS、CSS 和 OS,采用 Kaplan-Meier 法估计。
主要发现
- 中位随访 89.5 个月(范围 73-97 个月),72 Gy 组与 66 Gy 组 7 年 bPFS 分别为 70.3% 与 61.2%(HR 0.73,95%CI 0.41-1.29,P=.274),无显著差异。
- Gleason 评分 8-10 分患者中,72 Gy 组与 66 Gy 组 7 年 bPFS 分别为 66.5% 与 30.2%(HR 0.37,95%CI 0.17-0.82,P=.012),72 Gy 组显著改善。
- 多切缘阳性患者中,72 Gy 组与单切缘阳性患者 7 年 bPFS 分别为 82.5% 与 57.5%(HR 0.36,95%CI 0.13-0.99,P=.037),72 Gy 组显著改善。
- 72 Gy 组与 66 Gy 组 7 年 DMFS 分别为 88.4% 与 84.9%(HR 0.93,95%CI 0.39-2.23,P=.867),无显著差异。
- 72 Gy 组与 66 Gy 组 7 年 CSS 分别为 94.1% 与 95.5%(HR 1.19,95%CI 0.42-3.39,P=.745),7 年 OS 分别为 92.8% 与 94.1%(HR 1.29,95%CI 0.51-3.24,P=.594),均无显著差异。
局限性
- 原文结论指出,Gleason 评分 8-10 分或多切缘阳性患者可能从 72 Gy 方案获益,但需进一步前瞻性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In the randomized, single-center, PKUFH phase 3 trial, dose-intensified (72 Gy) radiation therapy was compared with conventional (66 Gy) radiation therapy. In a previous study, we found no significant difference in biochemical progression-free survival (bPFS) between the 2 cohorts at 4 years. In the current analysis, we provide 7-year outcomes. METHODS AND MATERIALS: Patients with stage pT3-4, positive surgical margins, or a prostate-specific antigen increase ≥0.2 ng/mL after radical prostatectomy were randomly assigned 1:1 to receive either 72 Gy in 36 fractions or 66 Gy in 33 fractions. All the patients underwent image guided intensity modulated radiation therapy. The primary endpoint was bPFS. Secondary endpoints were distant metastasis-free survival (DMFS), cancer-specific survival (CSS), and overall survival (OS) as estimated using the Kaplan-Meier method. RESULTS: Between September 2011 and November 2016, 144 patients were enrolled with 73 and 71 in the 72- and 66-Gy cohorts, respectively. At a median follow-up of 89.5 months (range, 73-97 months), there was no difference in 7-year bPFS between the 72- and 66-Gy cohorts (70.3% vs 61.2%; hazard ratio [HR], 0.73; 95% CI, 0.41-1.29; P = .274). However, in patients with a higher Gleason score (8-10), the 72-Gy cohort had statistically significant improvement in 7-year bPFS compared with the 66-Gy cohort (66.5% vs 30.2%; HR, 0.37; 95% CI, 0.17-0.82; P = .012). In addition, in patients with multiple positive surgical margins, the 72-Gy cohort had statistically significant improvement in 7-year bPFS compared with single positive surgical margin (82.5% vs 57.5%; HR, 0.36; 95% CI, 0.13-0.99; P = .037). The 7-year DMFS (88.4% vs 84.9%; HR, 0.93; 95% CI, 0.39-2.23; P = .867), CSS (94.1% vs 95.5%; HR, 1.19; 95% CI, 0.42-3.39; P = .745), and OS (92.8% vs 94.1%; HR, 1.29; 95% CI, 0.51-3.24; P = .594) had no statistical differences between the 72- and 66-Gy cohorts. CONCLUSIONS: The current 7-year bPFS results confirmed our previous findings that dose escalation (72 Gy) demonstrated no improvement in 7-year bPFS, DMFS, CSS, or OS compared with the 66-Gy regimen. However, patients with a higher Gleason score (8-10) or multiple positive surgical margins might benefit from the 72-Gy regimen, but this requires further prospective research.
引用
- Li HZ, Qi X, Gao XS, et al. Dose-Intensified Postoperative Radiation Therapy for Prostate Cancer: Long-Term Results From the PKUFH Randomized Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2023. PMID: 37717784. doi:10.1016/j.ijrobp.2023.09.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。